219 results match your criteria dcb des

Comparative effectiveness of endovascular treatment modalities for de novo femoropopliteal lesions in intermittent claudication: A network meta-analysis of randomized controlled trials.

Int J Cardiol 2021 Aug 27. Epub 2021 Aug 27.

Department of Vascular Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China; Department of Vascular Surgery, Fuwai Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China. Electronic address:

Purpose: To evaluate the most effective endovascular treatment modalities for de novo femoropopliteal lesions in intermittent claudication (IC) in terms of technical success, primary patency, target lesion revascularization (TLR) and all-cause mortality through network meta-analysis of randomized controlled trials.

Methods: Medical databases were searched on December 3, 2020. 16 studies (3265 patients) and 7 treatments were selected. Read More

View Article and Full-Text PDF

The clinical features and prognosis of type 4C myocardial infarction in patients with non-ST-segment elevation myocardial infarction.

Ann Transl Med 2021 Jul;9(14):1153

Thoracic Clinical College, Tianjin Medical University, Tianjin, China.

Background: Type 4C myocardial infarction (MI) is a special type of myocardial infarction related to restenosis without thrombosis. There is a lack of relevant data on this new classification of acute MI (AMI). This study set out to examine the prognosis and treatment of type 4C MI in patients with non-ST-segment elevation MI (NSTEMI). Read More

View Article and Full-Text PDF

Biomimetic, ROS-detonable nanoclusters - A multimodal nanoplatform for anti-restenotic therapy.

J Control Release 2021 Aug 18;338:295-306. Epub 2021 Aug 18.

Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, 22908, USA.. Electronic address:

The long-term success of endovascular intervention has long been overshadowed by vessel re-occlusion, also known as restenosis. Mainstream anti-restenotic devices, such as drug-eluting stent (DES) and drug-coated balloon (DCB), were recently shown with suboptimal performances and life-threatening complications, thereby underpinning the urgent need for alternative strategies with enhanced efficacy and safety profile. In our current study, we engineered a multimodal nanocluster formed by self-assembly of unimolecular nanoparticles and surface coated with platelet membrane, specifically tailored for precision drug delivery in endovascular applications. Read More

View Article and Full-Text PDF

Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents: The BASKET-SMALL 2 Trial.

JACC Cardiovasc Interv 2021 Aug;14(16):1789-1798

Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.

Objectives: The study sought to evaluate the impact of diabetes mellitus on 3-year clinical outcome in patients undergoing drug-coated balloon (DCB) or drug-eluting stent (DES) treatment for de novo lesions.

Background: For treatment of de novo coronary small vessel disease, DCBs are noninferior to DES.

Methods: In this prespecified analysis of a multicenter, randomized, noninferiority trial, including 758 patients with de novo lesions in coronary vessels <3 mm who were randomized 1:1 to DCB or DES and followed over 3 years for major adverse cardiac events (MACE) (cardiac death, nonfatal myocardial infarction [MI], and target vessel revascularization [TVR]), outcome was analyzed regarding the presence or absence of diabetes mellitus. Read More

View Article and Full-Text PDF

Coronary In-Stent Restenosis–Predictors and Treatment.

Dtsch Arztebl Int 2021 09 24(Forthcoming). Epub 2021 Sep 24.

Background: Despite the use of modern drug-eluting stents (DES), in-stent restenosis (ISR) may still occur in as many as 2-10% of percutaneous coronary interventions (PCI) in certain lesion/patient subsets. ISR causes increased morbidity after stent implantation; acute myocardial infarction is a frequent correlate to a clinical ISR, arising in 5-10% of cases. Compared to de novo stenosis, patients with ISR also present more frequently with symptoms of unstable angina pectoris (45% versus 61%). Read More

View Article and Full-Text PDF
September 2021

Aneurysmal Dilatation of the Superficial Femoral Artery After Endovascular Intervention.

JACC Case Rep 2021 Mar 17;3(3):425-426. Epub 2021 Mar 17.

Mount Sinai Heart, Mount Sinai Medical Center, New York, New York, USA.

A patient with occlusion of the left superficial femoral artery (SFA) underwent endovascular intervention. Six-month follow-up angiography revealed aneurysmal dilatation of the previously stented artery. This finding may be a result of maladaptive vascular remodeling or arterial injury resulting in aneurysmal dilatation secondary to subintimal crossing, atherectomy, and paclitaxel therapies. Read More

View Article and Full-Text PDF

[Position paper on endoscopic reporting in IBD].

Z Gastroenterol 2021 Jul 20. Epub 2021 Jul 20.

Medizinische Klinik 1, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

The complete and reliable documentation of endoscopic findings make up the crucial foundation for the treatment of patients with inflammatory bowel diseases such as Crohn´s disease and ulcerative colitis. These findings are, on the one hand, a prerequisite for therapeutic decisions and, on the other hand, important as a tool for assessing the response to ongoing treatments. Endoscopic reports should, therefore, be recorded according to standardized criteria to ensure that the findings of different endoscopists can be adequately compared and that changes in the course of the disease can be traced back. Read More

View Article and Full-Text PDF

Drug coated balloons for coronary artery bifurcation lesions: A systematic review and focused meta-analysis.

PLoS One 2021 9;16(7):e0251986. Epub 2021 Jul 9.

Department of Cardiology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, United Kingdom.

Objectives: We sought to systematically review the evidence supporting the role of drug coated balloons (DCBs) in the treatment of coronary bifurcation lesions.

Background: DCBs are emerging as an attractive alternative treatment strategy for treating coronary bifurcations due to simplifying the approach and reducing rates of stent related complications. We systematically reviewed the evidence for DCB use in coronary bifurcations and conducted a focused meta-analysis on late lumen loss in the side branch comparing DCB and plain old balloon angioplasty (POBA). Read More

View Article and Full-Text PDF

Association of mortality with drug-coated devices in femoropopliteal artery based on the nationwide data.

Ann Surg Treat Res 2021 Jul 30;101(1):20-27. Epub 2021 Jun 30.

Department of Physiology, Chung-Ang University School of Medicine, Seoul, Korea.

Purpose: Drug-coated devices have been widely accepted as one of the most promising therapies for femoropopliteal artery revascularization. A recent meta-analysis showed increased mortality in patients treated with drug-coated devices. We sought to examine the association between mortality and drug-coated devices after the treatment of the femoropopliteal artery based on the Korea national administrative claims data. Read More

View Article and Full-Text PDF

Intravascular coronary brachytherapy combined with a drug-coated balloon.

Brachytherapy 2021 Jul 2. Epub 2021 Jul 2.

Radiation Oncology, University of Washington, Seattle, WA.

Background: Coronary artery disease leads to stenosis of the major cardiac vessels, resulting in ischemia and infarction. Percutaneous intervention (PCI) with balloon angioplasty can re-open stenosed vessels. Drug eluting stents (DES) and intravascular brachytherapy (IVBT) and drug-coated balloons (DCBs) are proven to decrease the likelihood of another restenosis after PCI, but neither is completely effective. Read More

View Article and Full-Text PDF

Long-term Outcome following Percutaneous Intervention of Intra-stent Coronary Occlusion and Evaluating the Different Treatment Modalities.

Int J Cardiol Heart Vasc 2021 Jun 31;34:100803. Epub 2021 May 31.

Heartlands Hospital, University Hospitals Birmingham, United Kingdom.

Background: Angioplasty for ISR remains a challenge with relatively high rates of recurrence. Although there is a plethora of data on ISR, there is relatively less data on intra-stent-CTO. In this study, we explore the long-term clinical outcomes following angioplasty to intra-stent CTO and study the differences in clinical outcomes between three treatment-arms: POBA vs. Read More

View Article and Full-Text PDF

Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction.

J Cardiothorac Surg 2021 Jun 21;16(1):178. Epub 2021 Jun 21.

Xinhua Hospital Chongming Branch, Shanghai Jiaotong University, Nanmen Road, No. 25, Chongming District, Shanghai, 200000, China.

Background: Drug-coated balloon (DCB) is a new technology that has emerged in recent years and has been proven to be effective and safe in the treatment of in-stent restenosis. The purpose of this article is to observe the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction.

Method: We selected 80 patients admitted to the hospital for STEMI from January 2018 to December 2019. Read More

View Article and Full-Text PDF

Drug-delivering devices in the urinary tract: A systematic review.

Arab J Urol 2021 Mar 3;19(2):191-204. Epub 2021 Mar 3.

Endourological Society, Ureteral Stent Research Group.

Objective: : To systematically review the use of drug-eluting stents (DES) and drug-coated balloons (DCB) in urology.

Materials And Methods: The systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. PubMed, Scopus, Web of science and Cochrane Library online databases were searched in February 2019. Read More

View Article and Full-Text PDF

Directional atherectomy before paclitaxel coated balloon angioplasty in complex femoropopliteal disease: The VIVA REALITY study.

Catheter Cardiovasc Interv 2021 Sep 3;98(3):549-558. Epub 2021 Jun 3.

Department of Angiology, University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany.

Background: Drug coated balloon (DCB) angioplasty significantly reduces reintervention rates in patients with symptomatic femoropopliteal peripheral artery disease (PAD). However, stand-alone DCB use in long, severely calcified lesions is frequently associated with vessel recoil and/or high-grade dissections necessitating provisional stent implantation.

Objectives: Assess the safety and effectiveness of a vessel preparation strategy with directional atherectomy (DA) prior to DCB angioplasty in patients with symptomatic severely calcified femoropopliteal PAD. Read More

View Article and Full-Text PDF
September 2021

Intravascular Lithotripsy and Dual Drug-Coated Balloons for the Treatment of Severely Calcific Renal In-Stent Restenosis: All Is Fair in War.

Cardiovasc Revasc Med 2021 Jul 19;28S:193-196. Epub 2021 May 19.

Cardiovascular Research Team, San Carlo Clinic, Milano, Italy; Fondazione Ricerca e Innovazione Cardiovascolare, Milano, Italy. Electronic address:

Optimal treatment of renal artery "in-stent restenosis" (ISR) is still debated; drug eluting stents (DES), drug coated balloons (DCB) and scoring balloons have all been used, with mixed long term results. The shockwave lithotripsy for the treatment of heavily calcified atherosclerotic plaques has proven to be an effective tool and preliminary data support its use in case of underexpanded stents. Here we present the case of a 60 year old male with a known significant atherosclerotic renal artery stenosis and refractory hypertension who already underwent bilateral renal angioplasty with bare metal stents (BMS) in 2011 and angioplasty with DCB in 2012 for right renal artery ISR. Read More

View Article and Full-Text PDF

Clinical implication of quantitative flow ratio to predict clinical events after drug-coated balloon angioplasty in patients with in-stent restenosis.

Clin Cardiol 2021 Jul 19;44(7):978-986. Epub 2021 May 19.

Department of Cardiology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

Background: The association between the quantitative flow ratio (QFR) and adverse events after drug-coated balloon (DCB) angioplasty for in-stent restenosis (ISR) lesions has not been investigated.

Hypothesis: Post-procedural QFR is related to adverse events in patients undergoing DCB angioplasty for ISR lesions.

Methods: This retrospective study included data from patients undergoing DCB angioplasty for drug-eluting stent (DES) ISR between January 2016 and February 2019. Read More

View Article and Full-Text PDF

Tackling the Challenges of Product Development Through a Collaborative Rare Disease Network: The Foundation Fighting Blindness Consortium.

Transl Vis Sci Technol 2021 04;10(4):23

Institut de la Vision, Sorbonne Université, INSERM, CNRS, Paris, France.

The Foundation Fighting Blindness, a 501(c)(3) nonprofit organization, established an international consortium of inherited retinal disease specialists in 2016, with a mission to accelerate the development of treatments for rare, inherited retinal degenerations, such as retinitis pigmentosa, Stargardt disease, Leber congenital amaurosis, Usher syndrome, choroideremia, and achromatopsia. The Consortium accomplishes its mission by evaluating novel outcome measures, sharing standardized study protocols and datasets, and disseminating findings. Having established research infrastructure in the first 3 years, including 39 global research sites, the network is now poised to expand its infrastructure for trials of new therapies in partnership with industry. Read More

View Article and Full-Text PDF

Drug-Coated Balloon versus Drug-Eluting Stent in Patients with Small-Vessel Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials.

Cardiol Res Pract 2021 13;2021:1647635. Epub 2021 Apr 13.

Department of Cardiology, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Han Zheng Street 473, Wuhan 430033, China.

Background: Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) of small-vessel coronary artery disease (SVD) is related to an increased risk of in-stent restenosis (ISR) and stent thrombosis (ST). The application of the drug-coated balloon (DCB) for patients with SVD remains controversial.

Objectives: Assess the outcomes of DCB in the treatment of SVD compared with DES in patients with SVD. Read More

View Article and Full-Text PDF

Results of paclitaxel-drug-coated balloons (Pantera Lux) for coronary in-stent restenosis: Italian experience from REGistry of Paclitaxel Eluting Balloon in ISR study.

J Cardiovasc Med (Hagerstown) 2021 Jun;22(6):469-477

Cardiologia Invasiva 2, Centro Cardiologico Fondazione Monzino IRCCS.

Aims: Drug-eluting stent (DES) implantation is an effective treatment of in-stent restenosis (ISR). However, literature data indicate that drug-coated balloons (DCBs) may be a valid alternative, particularly for recurrent ISR. We sought to evaluate clinical results on the long-term efficacy of a new DCB for ISR treatment. Read More

View Article and Full-Text PDF

Outcomes with drug-coated balloons vs. drug-eluting stents in small-vessel coronary artery disease.

Cardiovasc Revasc Med 2021 Mar 20. Epub 2021 Mar 20.

Minneapolis Heart Institute, Minneapolis, MN, USA. Electronic address:

Background: The use of drug-coated balloons (DCBs) in small-vessel coronary artery disease (SVD) remains controversial.

Methods: We performed a meta-analysis of all randomized controlled trials (RCTs) reporting the outcomes of DCB vs. DES in de-novo SVD. Read More

View Article and Full-Text PDF

Early coronary healing in ST segment elevation myocardial infarction: sirolimus-eluting stents vs. drug-coated balloons after bare-metal stents. The PEBSI-2 optical coherence tomography randomized study.

Coron Artery Dis 2021 Mar 16. Epub 2021 Mar 16.

Interventional Cardiology, Hospital Puerta de Hierro Majadahonda Interventional Cardiology, Hospital Clínico San Carlos, Madrid Interventional Cardiology, Hospital Univeritari de Bellvitge, L'Hospitalet de Llobregat Department of Cardiology, Clinic Thorax Institute, Hospital Clinic de Barcelona Department of Cardiology, Hospital Son Espases, Mallorca Department of Cardiology, Puerto Real University Hospital, Cadiz Unidad de Cardiología Intervencionista, Departamento de Cardiología, Hospital del Mar, Barcelona Interventional Cardiology, Hospital Ramon y Cajal Servicio de Cardiología, Hospital Universitario 12 de Octubre Department of Cardiology, Hospital Universitario de La Princesa, CIBER-CV, IIS-IP, Madrid, Spain.

Objectives: Drug-coated balloons (DCBs) have theoretical advantages over drug-eluting stents (DESs) to facilitate stent healing. We studied whether, in patients undergoing primary coronary interventions (pPCIs), a strategy of DCB after bare-metal stent improves early healing as determined by optical coherence tomography (OCT) compared with new-generation DES.

Methods: pPCI patients were randomized (1:1) to treatment with new-generation sirolimus-eluting stents (DES group) or DCB-strategy. Read More

View Article and Full-Text PDF

Impact of optimal preparation before drug-coated balloon dilatation for de novo lesion in patients with coronary artery disease.

Cardiovasc Revasc Med 2021 Mar 20. Epub 2021 Mar 20.

Department of Cardiology, Toyohashi Heart Center, Aichi, Japan.

Background: Drug eluting stent (DES) remain several problems, including stent thrombosis, stent fracture and neoatherosclerosis. Stent-less Percutaneous coronary intervention (PCI) using a drug coated balloon (DCB) is a stent-less strategy, and several trials have supported the efficacy of DCB. However, the optimal preparation before using DCB was uncertain. Read More

View Article and Full-Text PDF

Prognostic value of quantitative flow ratio measured immediately after drug-coated balloon angioplasty for in-stent restenosis.

Catheter Cardiovasc Interv 2021 May 20;97 Suppl 2:1048-1054. Epub 2021 Mar 20.

Department of Cardiology, PLA General Hospital, Beijing, China.

Objectives: This study aimed to evaluate prognostic value of quantitative flow ratio (QFR) in drug-coated balloon (DCB) angioplasty for in-stent restenosis (ISR).

Background: There is a high incidence of recurrent ISR after DCB angioplasty. QFR is a novel method for fast computation of fractional flow reserve for the target vessel based on quantitative coronary angiography (QCA) and fluid dynamics algorithms. Read More

View Article and Full-Text PDF

A Non-inferiority, Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus New-Generation Drug-Eluting Stents on Angiographic Outcomes for Coronary De Novo Lesions.

Cardiovasc Drugs Ther 2021 Mar 13. Epub 2021 Mar 13.

Department of Cardiology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, 100730, Beijing, P. R. China.

Background: Drug-coated balloon (DCB) has been proved efficacy for coronary small vessel disease, but data regarding outcomes of DCB in common de novo lesions (including reference vessel diameter more than 3.0mm) compared with new-generation drug-eluting stent (DES) are lacking. We hypothesized that a DCB-only strategy for coronary de novo lesions would be non-inferior to DES treatment on angiographic outcomes. Read More

View Article and Full-Text PDF

Restenosis of a drug eluting stent on the previous bioresorbable vascular scaffold successfully treated with a drug-coated balloon: A case report.

World J Clin Cases 2021 Jan;9(3):758-763

Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, South Korea.

Background: The in-stent restenosis (ISR) rates are reportedly inconsistent despite the increased use of second-generation drug eluting stent (DES). Although bioresorbable vascular scaffold (BVS) have substantial advantages with respect to vascular restoration, the rate of scaffold thrombosis is higher with BVS than with DES. Optimal treatment strategies have not been established for DES-ISR to date. Read More

View Article and Full-Text PDF
January 2021

Comparative performance analysis of interventional devices for the treatment of ischemic disease in below-the-knee lesions: a systematic review and meta-analysis.

Cardiovasc Interv Ther 2021 Feb 6. Epub 2021 Feb 6.

Cooperative Major in Advanced Biomedical Sciences, Graduate School of Advanced Science and Engineering, Joint Graduate School of Tokyo Women's Medical University, Waseda University, 2-2 Wakamatsu-cho, Shinjuku, Tokyo, 162-8480, Japan.

This meta-analysis aimed to evaluate the device performance of conventional balloon catheters (POBA), drug-coated balloons (DCB), bare-metal stents (BMS), and drug-eluting stents (DES) in below-the-knee (BTK) ischemic lesions with regard to lesion characteristics. Online searches of PubMed, Web of Science, and Cochrane databases (2010-2019) were conducted for each of the test devices. Primary patency rates (pp) and major amputation rates 1 year after the use of each device were analyzed using a random-effects meta-analysis model. Read More

View Article and Full-Text PDF
February 2021

[Proper lighting for color vision testing: The TRUE COLOR LED lamp - an innovation in this field].

J Leid G Kraft

J Fr Ophtalmol 2021 Feb 4;44(2):224-238. Epub 2020 Dec 4.

Centre ophtalmologique Futura, 19 rue de la Glacière, 69300 Schiltigheim, France.

Given the latest trend in light sources, and in particular, the widespread use of LED lamps, we began to rethink the old lighting standards for colour vision testing. We (J. Leid) therefore conceived a new, easy to use, calibrated lamp with a specific ergonomic design, emitting light with a spectrum close to that of the standard D65, and perfectly adapted to pigmentary colour vision tests. Read More

View Article and Full-Text PDF
February 2021

Drug-Coated Balloon Versus Drug-Eluting Stent for Small Coronary Vessel Disease: PICCOLETO II Randomized Clinical Trial.

JACC Cardiovasc Interv 2020 12 25;13(24):2840-2849. Epub 2020 Nov 25.

Cardiology Department, Hospital de la Princesa, Madrid, Spain.

Objectives: This study sought to compare the performance of a novel drug-coated balloon (DCB) (Elutax SV, Aachen Resonance, Germany), with an everolimus-eluting stent (EES) (Abbott Vascular, Santa Clara, California) in patients with de novo lesions.

Background: Small vessel coronary artery disease (SVD) represents one of the most attractive fields of application for DCB. To date, several devices have been compared with drug-eluting stents in this setting, with different outcomes. Read More

View Article and Full-Text PDF
December 2020